Cargando…

Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy

There is growing interest in cost-effectiveness thresholds as a tool to inform resource allocation decisions in health care. Studies from several countries have sought to estimate health system opportunity costs, which supply-side cost-effectiveness thresholds are intended to represent. In this pape...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sampson, Chris, Zamora, Bernarda, Watson, Sam, Cairns, John, Chalkidou, Kalipso, Cubi-Molla, Patricia, Devlin, Nancy, García-Lorenzo, Borja, Hughes, Dyfrig A., Leech, Ashley A., Towse, Adrian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385803/ https://www.ncbi.nlm.nih.gov/pubmed/35668345 http://dx.doi.org/10.1007/s40258-022-00730-3

Ejemplares similares

The cost-per-QALY threshold in England: Identifying structural uncertainty in the estimates
por: Zamora, Bernarda, et al.
Publicado: (2023)

Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB
por: Chalkidou, Kalipso, et al.
Publicado: (2020)

How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine?
por: Towse, Adrian, et al.
Publicado: (2021)

Mapping Priority Setting in Health in 17 Countries Across Asia, Latin America, and sub-Saharan Africa
por: Li, Ryan, et al.
Publicado: (2016)

Editorial: Opportunity costs in health care: cost-effectiveness thresholds and beyond
por: Sampson, Chris, et al.
Publicado: (2023)

Estimating health system opportunity costs: the role of non-linearities and inefficiency
por: Hernandez-Villafuerte, Karla, et al.
Publicado: (2022)

Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?
por: Cubi-Molla, Patricia, et al.
Publicado: (2021)

Reconciling ACEA and MCDA: is there a way forward for measuring cost-effectiveness in the U.S. healthcare setting?
por: Zamora, Bernarda, et al.
Publicado: (2021)

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support
por: Garrison, Louis P., et al.
Publicado: (2020)

The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review
por: Kazibwe, Joseph, et al.
Publicado: (2022)

A note on the relationship between age and health-related quality of life assessment
por: Cubi-Molla, Patricia, et al.
Publicado: (2018)

Sharing the British National Health Service around the world: a self-interested perspective
por: Chalkidou, Kalipso, et al.
Publicado: (2013)

Economic Evaluation for Health Investments En Route to Universal Health Coverage: Cost-Benefit Analysis or Cost-Effectiveness Analysis?
por: Culyer, Anthony J., et al.
Publicado: (2019)

Should Countries Set an Explicit Health Benefits Package? The Case of the English National Health Service()
por: Smith, Peter C, et al.
Publicado: (2017)

Organising Research and Development for evidence-informed health care: some universal characteristics and a case study from the UK
por: Culyer, Anthony J., et al.
Publicado: (2021)

Accreditation as a quality-improving policy tool: family planning, maternal health, and child health in Egypt
por: El-Shal, Amira, et al.
Publicado: (2020)

Supporting the Development of Evidence-Informed Policy Options: An Economic Evaluation of Hypertension Management in Ghana
por: Gad, Mohamed, et al.
Publicado: (2020)

Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L
por: Herdman, Michael, et al.
Publicado: (2020)

Renal transplant patients’ preference for the supply and delivery of immunosuppressants in Wales: a discrete choice experiment
por: Hagemi, Anke, et al.
Publicado: (2017)

The Other Side of the Question
Publicado: (1914)

Rival perspectives in health technology assessment and other economic evaluations for investing in global and national health. Who decides? Who pays?
por: Culyer, Anthony, et al.
Publicado: (2018)

Health Technology Assessment capacity development in low- and middle-income countries: Experiences from the international units of HITAP and NICE
por: Tantivess, Sripen, et al.
Publicado: (2017)

Incorporating MCDA into HTA: challenges and potential solutions, with a focus on lower income settings
por: Marsh, Kevin, et al.
Publicado: (2018)

Value-based tiered pricing for universal health coverage: an idea worth revisiting
por: Chalkidou, Kalipso, et al.
Publicado: (2020)

Disease Control Priorities Third Edition: Time to Put a Theory of Change Into Practice: Comment on "Disease Control Priorities Third Edition Is Published: A Theory of Change Is Needed for Translating Evidence to Health Policy"
por: Isaranuwatchai, Wanrudee, et al.
Publicado: (2018)

Supply-side and demand-side policies for biosimilars: an overview in 10 European member states
por: Rémuzat, Cécile, et al.
Publicado: (2017)

We need a NICE for global development spending
por: Chalkidou, Kalipso, et al.
Publicado: (2017)

Health technology assessment capacity at national level in sub-Saharan Africa: an initial survey of stakeholders
por: Hollingworth, Samantha A., et al.
Publicado: (2021)

Capacity for health economics research and practice in Jordan, Lebanon, the occupied Palestinian territories and Turkey: needs assessment and options for development
por: Gheorghe, Adrian, et al.
Publicado: (2020)

Medical training for universal health coverage: a review of Cuba–South Africa collaboration
por: Squires, Neil, et al.
Publicado: (2020)

Charging for the use of survey instruments on population health: the case of quality-adjusted life years
por: Teerawattananon, Yot, et al.
Publicado: (2020)

The journey to UHC: how well are vertical programmes integrated in the health benefits package? A scoping review
por: Regan, Lydia, et al.
Publicado: (2021)

Evidence-Informed Deliberative Processes for HTA Around the Globe: Exploring the Next Frontiers of HTA and Best Practices Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe"
por: Gopinathan, Unni, et al.
Publicado: (2020)

Approaches to Measure Efficiency in Primary Care: A Systematic Literature Review
por: Neri, Margherita, et al.
Publicado: (2021)

The Other Side of the Vaccination Question
Publicado: (1902)

The Other Side of the Opium Question
Publicado: (1882)

A theory on ICER pricing and optimal levels of cost-effectiveness thresholds: a bargaining approach
por: Berdud, Mikel, et al.
Publicado: (2023)

How Should Global Fund Use Value-for-Money Information to Sustain its Investments in Graduating Countries?
por: Kanpirom, Kitti, et al.
Publicado: (2017)

Lockdown is not egalitarian: the costs fall on the global poor
por: Broadbent, Alexander, et al.
Publicado: (2020)

Opportunity costs and local health service spending decisions: a qualitative study from Wales
por: Karlsberg Schaffer, Sarah, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4m21i2b8hjl036m1htn355a2r3